BravoVax CEO was Invited to Attend “Biopharmaceutical Innovation and Development Summit 2022”

On July 19-20th, 2022, “Biopharmaceutical Innovation and Development Summit 2022” was held in Beijing, China. KOLs from biopharm industry were invited to the Summit, and shared their insightful views on current R&D innovation, production, application and technical obstacles in this domain. Dr. Wu Ke, CEO of BravoBio, was invited as the host for "mRNA Technologies and COVID-19 Vaccine Development" session, and gave a keynote speech on "Ideal Development Strategies for COVID-19 Vaccine". 

 In the speech, Dr. Wu, not only shared the development strategies of COVID-19 vaccine, but also demonstrated the development pathway of Pan-Sarbecovirus vaccine at BravoBio. 

In Dec. 2021, BravoBio signed the cooperation agreement with Professor Jiang Shibo's team of Fudan University and Fulgent Genetics to jointly develop a broad-spectrum Beta-coronavirus lineage B vaccine. We expect this vaccine could be pushed into the clinical stage as soon as possible, under the joint efforts of the three parties, thus benefiting the global health.